Sp1046
AGA GUIDELINE: BIOMARKERS FOR MONITORING INFLAMMATION IN IBD
Date
May 9, 2023
Explore related products in the following collection:
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
REAL WORLD IMPLEMENTATION OF TREAT-TO-TARGET IN PATIENTS WITH IBD IN A LEARNING HEALTH SYSTEM: AN IBD QORUS COLLABORATIVE STUDY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…